Se. Mclinn et al., COMPARISON OF CEFUROXIME AXETIL AND AMOXICILLIN-CLAVULANATE SUSPENSIONS IN TREATMENT OF ACUTE OTITIS-MEDIA WITH EFFUSION IN CHILDREN, Antimicrobial agents and chemotherapy, 38(2), 1994, pp. 315-318
Two hundred sixty-three pediatric patients from the ages of 3 months t
o 11 years were enrolled in a randomized, investigator-blinded, multic
enter study comparing the clinical and bacteriological efficacies and
safety of cefuroxime axetil suspension (CAE) with those of amoxicillin
-clavulanate suspension (AMX-CL) in the treatment of acute otitis medi
a with effusion. Patients received CAE at 30 mg/kg of body weight per
day (n = 165) in two divided doses or AMX-CL at 40 mg/kg/day (n = 98)
in three divided doses for 10 days. The primary pathogens among 200 is
olates from pretreatment cultures of middle ear fluid were identified
as follows: Haemophilus influenzae (39%), over a third of which were b
eta-lactamase positive; Streptococcus pneumoniae (34%); and Moraxella
catarrhalis (16%). Pathogens were eradicated or presumed to be eradica
ted from 81% (95 of 118) and 76% (50 of 66) of bacteriologically evalu
able patients in the CAE and AMX-CL groups, respectively. A satisfacto
ry clinical response (cure or improvement with or without resolution o
f effusion) occurred in 113 (77%) of 146 clinically evaluable patients
in the CAE group and in 66 (74%) of 89 evaluable patients in the AMX-
CL group. Clinical failure or recurrence (within 2 weeks following the
completion of treatment) occurred in 22 and 26% of CAE- and AMX-CL-tr
eated patients, respectively. Drug-related adverse events occurred in
18% of CAE-treated patients, whereas they occurred in 39% of AMX-CL-tr
eated patients (P<0.001); diarrhea or loose stools was the most common
ly reported adverse event (CAE, 12%; AMX-CL, 31%; P<0.001). These resu
lts indicate that CAE given t-vvice daily is as effective as AMX-CL gi
ven three times daily in the treatment of acute otitis media with effu
sion in pediatric patients, but CAE was associated with significantly
fewer drug-related adverse events.